Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce the launch of the new Oxford Centre for Neuroinflammation (OCNI), which aims to shed light on the causes of neurodegenerative diseases and uncover new treatment pathways

© John Cairns

Headed by Professor Lars Fugger, the centre will bring together biomedical, analytical and clinical expertise, to investigate the neuroinflammatory mechanisms that underpin a range of neurodegenerative diseases including multiple sclerosis, Parkinson’s and Alzheimer’s. This will allow our researchers to develop new tools for faster diagnosis, more accurate prognosis and new targets for life-changing and life-saving treatments.

We hope that the opening of the OCNI will help accelerate our understanding of neurodegenerative diseases and thus pave the way for novel treatments for patients worldwide - Professor Lars Fugger

In particular, the OCNI will capitalise on recent technological advances, including next generation experimental platforms, genetic microsurgery techniques and single-cell analysis methods, as well as on the on-going ‘big data’ explosion, which is enabling access to genetic, clinical and epidemiological information from hundreds of thousands of patients. By combining cutting-edge scientific approaches with clinically relevant data sets and with direct access to patient samples, the OCNI will be uniquely placed to drive forward medical research, interrogating the neuroinflammatory basis of neurodegenerative diseases.

Funded by the Oak Foundation and private donors the centre will ensure that new findings within the field are translated back to real progress in the clinic. The centre will focus on four major goals:

  1. Understanding how genetic information can be harnessed to help facilitate diagnosis
  2. Investigating the interplay between environmental factors and disease
  3. Establishing how to predicted drug efficacy
  4. Ascertaining whether drugs already tested and approved can be re-purposed for the treatment of neurodegenerative disease.

By addressing these questions, the centre will help to provide life changing therapeutic options to enable patients worldwide to live active and fulfilling lives. 

Find out more 

Similar stories

Kia Nobre steps down as Head of Department

Matthew Rushworth replaces Kia Nobre as interim Head of the Department of Experimental Psychology

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Experimental Medicine and Industry Partnership

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.